The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: A phase 3 children's oncology group/pediatric blood and marrow transplant consortium trial

Blood

Volumn 123, Issue 13, 2014, Pages 2017-2025

  Pulsipher, Michael A ^a   Langholz, Bryan ^b   Wall, Donna A ^c   Schultz, Kirk R ^d   Bunin, Nancy ^e,m   Carroll, William L ^a   Raetz, Elizabeth ^a   Gardner, Sharon ^f   Gastier Foster, Julie M ^g   Howrie, Denise ^h   Goyal, Rakesh K ^h   Douglas, James G ⁱ   Borowitz, Michael ^j   Barnes, Yvonne ^k   Teachey, David T ^e,m   Taylor, Candace ^l   Grupp, Stephan A ^e,m  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Manitoba Blood and Marrow Transplant Program   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^h CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j DEPARTMENT OF PATHOLOGY   (United States)

^k WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l Methodist Children's Hospital of South Texas   (United States)

^m UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; METHOTREXATE; RAPAMYCIN; TACROLIMUS; THIOTEPA;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADD ON THERAPY; ADOLESCENT; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; VEIN OCCLUSION; WHOLE BODY RADIATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; METHOTREXATE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIROLIMUS; TACROLIMUS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION; YOUNG ADULT;

EID: 84897494651     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-10-534297     Document Type: Article

References (39)

1. Eapen M, Raetz E, Zhang MJ, et al Children's Oncology Group; Center for International Blood and Marrow Transplant Research. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood. 2006;107(12):4961-4967. (Pubitemid 43882651)
2. Borgmann A, von Stackelberg A, Hartmann R, et al Berlin-Frankfurt- Münster Relapse Study Group. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood. 2003;101(10):3835-3839. (Pubitemid 36857854)
3. Oliansky DM, Camitta B, Gaynon P, et al. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review [published correction appears in Biol Blood Marrow Transplant. 2012;18(9):1466]. Biol Blood Marrow Transplant. 2012;18(4):505-522.
4. MacMillan ML, Davies SM, Nelson GO, et al. Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant. 2008;14(suppl 9):16-22.
5. Harvey J, Green A, Cornish J, et al. Improved survival in matched unrelated donor transplant for childhood ALL since the introduction of high-resolution matching at HLA class I and II. Bone Marrow Transplant. 2012;47(10):1294-1300.
6. Pulsipher MA, Bader P, Klingebiel T, Cooper LJ. Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biol Blood Marrow Transplant. 2009;15(Suppl 1):62-71.
7. Brown VI, Fang J, Alcorn K, et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci U S A. 2003;100(25):15113-15118. (Pubitemid 37518025)
8. Teachey DT, Obzut DA, Cooperman J, et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood. 2006;107(3):1149-1155. (Pubitemid 43156317)
9. Teachey DT, Sheen C, Hall J, et al. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood. 2008;112(5):2020-2023.
10. Antin JH, Kim HT, Cutler C, et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003;102(5):1601-1605. (Pubitemid 37022548)
11. Pulsipher MA, Wall DA, Grimley M, et al. A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol. 2009;147(5):691-699.
12. Armand P, Gannamaneni S, Kim HT, et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2008;26(35):5767-5774.
13. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3):549-556. (Pubitemid 10242750)
14. Freidlin B, Korn EL. A comment on futility monitoring. Control Clin Trials. 2002;23(4):355-366. (Pubitemid 34874888)
15. Borowitz MJ, Wood BL, Devidas M, et al. Improved post-induction chemotherapy does not abrogate prognostic significance of minimal residual disease (MRD) for children and young adults with high risk acute lymphoblastic leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232 [abstract]. Blood. 2011;18(21). Abstract 1440.
16. Dworzak MN, Fröschl G, Printz D, et al Austrian Berlin-Frankfurt- Münster Study Group. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002;99(6):1952-1958. (Pubitemid 34525474)
17. Borowitz MJ, Pullen DJ, Shuster JJ, et al. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study. Leukemia. 2003;17(8):1566-1572. (Pubitemid 36986959)
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
19. Cox D. Regression models and life tables. J R Stat Soc B. 1972;34:187-202.
20. Aalen O, Johansen S. An empirical transition matrix for nonhomogeneous Markov chains based on censored observations. Scand J Stat. 1978;5:141-150.
21. Cutler C, Henry NL, Magee C, et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(7):551-557. (Pubitemid 40862452)
22. Cutler C, Stevenson K, Kim HT, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008;112(12):4425-4431.
23. Cutler C, Kim HT, Hochberg E, et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2004;10(5):328-336. (Pubitemid 38519571)
24. Collins RH Jr, Goldstein S, Giralt S, et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant. 2000;26(5):511-516.
25. Levine JE, Barrett AJ, Zhang MJ, et al. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplant. 2008;42(3):201-205.
26. Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28(23):3730-3738.
27. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3):555-562. (Pubitemid 20069191)
28. Cornelissen JJ, Carston M, Kollman C, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood. 2001;97(6):1572-1577. (Pubitemid 32217219)
29. Passweg JR, Tiberghien P, Cahn JY, et al. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant. 1998;21(2):153-158. (Pubitemid 28044008)
30. Lee S, Cho BS, Kim SY, et al. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13(9):1083-1094. (Pubitemid 47215565)
31. Nordlander A, Mattsson J, Ringden O, et al. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2004;10(3):195-203. (Pubitemid 38262882)
32. Zikos P, Van Lint MT, Lamparelli T, et al. Allogeneic hemopoietic stem cell transplantation for patients with high risk acute lymphoblastic leukemia: favorable impact of chronic graft-versus-host disease on survival and relapse. Haematologica. 1998;83(10):896-903. (Pubitemid 28538443)
33. Locatelli F, Zecca M, Messina C, et al. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. Leukemia. 2002;16(11):2228-2237. (Pubitemid 35331838)
34. Gustafsson Jernberg A, Remberger M, Ringdén O, Winiarski J. Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival. Bone Marrow Transplant. 2003;31(3):175-181. (Pubitemid 36305571)
35. Dini G, Zecca M, Balduzzi A, et al; Associazione Italiana Ematologia ed Oncologia Pediatrica - Hematopoietic Stem Cell Transplantation (AIEOP-HSCT) Group. No difference in outcome between children and adolescents transplanted for acute lymphoblastic leukemia in second remission. Blood. 2011;118(25):6683-6690.
36. Bader P, Kreyenberg H, Henze GH, et al ALL-REZ BFM Study Group. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol. 2009;27(3):377-384.
37. Elorza I, Palacio C, Dapena JL, Gallur L, Sánchez de Toledo J, Díaz de Heredia C. Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia. Haematologica. 2010;95(6):936-941.
38. Leung W, Pui CH, Coustan-Smith E, et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood. 2012;120(2):468-472.
39. Foster JH, Hawkins DS, Loken MR, Wells DA, Thomson B. Minimal residual disease detected prior to hematopoietic cell transplantation. Pediatr Blood Cancer. 2011;57(1):163-165.